9.33

0.64% -0.06

Immunome Inc (IMNM)

Overview News Price History Option Chain Financials Discussions Forecast

Immunome Inc stock is traded at $9.33, with a volume of 550.35K. It is down -0.64% in the last 24 hours and down -24.02% over the past month. Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Previous Close:

$9.39

Open:

$9.29

24h Volume:

550.35K

Relative Volume:

0.83

Market Cap:

$561.50M

Revenue:

Net Income/Loss:

$-106.81M

P/E Ratio:

-4.2409

EPS:

-2.2

Net Cash Flow:

$-8.40M

1W Performance:

-19.50%

1M Performance:

-24.02%

6M Performance:

-32.39%

1Y Performance:

+19.77%

1-Day Range:

$8.97

$9.36

1-Week Range:

$8.97

$11.66

52-Week Range:

$6.93

$30.96

Immunome Inc Stock (IMNM) Company Profile

Name

Immunome Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

610-321-3700

Address

18702 N. CREEK PARKWAY, BOTHELL

Employee

105

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IMNM's Discussions on Twitter

Compare IMNM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMNM	9.33	561.50M	0	-106.81M	-8.40M	-2.20
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-31-24	Initiated	Piper Sandler	Overweight
Apr-30-24	Initiated	JP Morgan	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Jan-29-24	Initiated	Leerink Partners	Outperform
Dec-19-23	Initiated	Wedbush	Outperform
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight

View All

Immunome Inc Stock (IMNM) Latest News

Nov 18, 2024

Immunome Inc. Announces Third Quarter 2024 Financial Results and Pipeline Progress - Defense World

Nov 16, 2024

Nov 15, 2024

Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 15, 2024

Immunome (NASDAQ:IMNM) Stock Price Down 7% After Analyst Downgrade - Defense World

Nov 15, 2024

Nov 14, 2024

T. Rowe Price Investment Management, Inc. Expands Stake in Immun - GuruFocus.com

Nov 14, 2024

Piper Sandler maintains overweight on IMNM with $21 target By Investing.com - Investing.com Canada

Nov 14, 2024

Piper Sandler maintains overweight on IMNM with $21 target - Investing.com India

Nov 14, 2024

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace

Nov 14, 2024

Janus Henderson Group's Strategic Acquisition of Immunome Inc Sh - GuruFocus.com

Nov 14, 2024

Immunome (NASDAQ:IMNM) Shares Down 7% Following Analyst Downgrade - MarketBeat

Nov 14, 2024

Piper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00 - MarketBeat

Nov 14, 2024

Immunome price target lowered to $21 from $23 at Piper Sandler - TipRanks

Nov 14, 2024

Nov 13, 2024

Immunome, Inc. Reports Q3 2024 Financial Results - TipRanks

Nov 13, 2024